In the Claims:

Please amend the claims as follows:

1. (Currently Amended) A compound of formula (I):



(I)

wherein:

Y is phenyl, substituted with one, two or three substituents selected from C_{1-6} alkyl, halosubstitutedC_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, cyano, halo, C_{1-6}alkylsulfonyl, COOH, halosubstitutedC_{1-6} alkoxy, $CONH_2$, $NHCOCH_3$, C_{1-6}alkynyl, C_{1-6}alkyenyl $SO_2NR^{8a}R^{8b}$ wherein R^{8a} and R^{8b} are independently selected from H and C_{1-6}alkyl;

R^1 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, and halosubstitutedC_{1-6} alkyl;

R^2 is $(CH_2)mR^3$;

R^3 is a [[an]] 5- to 6- membered aromatic heterocyclyl group unsubstituted or substituted with 1, 2 or 3 substitutents selected from C_{1-6} alkyl, C_{1-6} alkoxy, halosubstitutedC_{1-6} alkoxy, halosubstitutedC_{1-6} alkyl, hydroxy, cyano, halo, sulfonyl, $CONH_2$ and COOH, or group A:



(A)

R^4 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, or halosubstitutedC_{1-6} alkyl, $COCH_3$, and SO_2Me;

R^6 is unsubstituted or substituted (C_{1-6})alkyl or chloro and R^{10} is hydrogen or R^{10} is unsubstituted or substituted (C_{1-6})alkyl or chloro and R^6 is hydrogen wherein said substituted (C_{1-6})alkyl is substituted with 1, 2 or 3

substitutents selected from hydroxy, C_{1-6}alkyoxy, cyano, halo, $NR^{8a}R^{8b}$, $CONR^{8a}R^{8b}$, $SO_2NR^{8a}R^{8b}$, $NR^{8a}COR^{8b}$ and $NR^{8a}SO_2R^{8b}$;

Ra is independently selected from hydrogen, fluoro, chloro and trifluoromethyl;

Rb is independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, halo substituted C_{1-6} alkoxy, hydroxy, cyano, halo, sulfonyl, $CONH_2$, COOH, SO_2CH_3, $NHCOCH_3$, $NHSO_2CH_3$ and $CONHCH_3$;

m is 1 or 2;

or a pharmaceutically acceptable salt ~~derivative~~ thereof.

2. (Previously presented) A compound of formula (Ia):



(Ia)

wherein

R^1 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, and halosubstitutedC_{1-6} alkyl;

R^3 is furanyl, dioxalanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, triazinyl, isothiazolyl, isoxazolyl, thienyl, pyrazolyl, tetrazolyl, pyridyl, pyrizinyl, pyrimidinyl, pyrazinyl, triazinyl, or tetrazinyl which can be unsubstituted or substituted with 1, 2 or 3 substitutents selected from C_{1-6} alkyl, C_{1-6} alkoxy, halosubstitutedC_{1-6} alkoxy, halosubstitutedC_{1-6} alkyl, hydroxy, cyano, halo, sulfonyl, $CONH_2$ and COOH, or R^3 is group A:



(A)

R^4 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, or

halosubstitutedC_{1-6} alkyl, $COCH_3$, and SO_2Me;

R^6 is unsubstituted or substituted (C_{1-6})alkyl, chloro and R^{10} is hydrogen or R^{10} is unsubstituted or substituted (C_{1-6})alkyl or chloro and R^6 is hydrogen wherein said substituted (C_{1-6})alkyl is substituted with 1, 2 or 3 substitutents selected from hydroxy, C_{1-6}alkyoxy, cyano, halo, $NR^{8a}R^{8b}$, $CONR^{8a}R^{8b}$, $SO_2NR^{8a}R^{8b}$, $NR^{8a}COR^{8b}$ and $NR^{8a}SO_2R^{8b}$;

Ra is independently selected from hydrogen, fluoro, chloro and trifluoromethyl;

Rb is independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, halosubstitutedC_{1-6} alkoxy, hydroxy, cyano, halo, sulfonyl, $CONH_2$, $COOH$, SO_2CH_3, $NHCOCH_3$, $NHSO_2CH_3$ and $CONHCH_3$;

R^{11} is C_{1-6} alkyl, halosubstitutedC_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, cyano, halo, C_{1-6}alkylsulfonyl, $CONH_2$, $NHCOCH_3$, $COOH$, halosubstitutedC_{1-6} alkoxy, C_{1-6}alkynyl, C_{1-6}alkynyl, $SO_2NR^{8a}R^{8b}$;

d is 1, 2, or 3:

m is 1 or 2;

R^{8a} and R^{8b} are independently selected from hydrogen and C_{1-6}alkyl;

or a pharmaceutically acceptable salt ~~derivative~~ thereof.

3. (Previously presented) A compound as claimed in claim 1 wherein R^1 is hydrogen or C_{1-6}alkyl

4. (Previously presented) A compound as claimed in claim 1 wherein R^4 is hydrogen or methyl.

5. (Previously presented) A compound as claimed in claim 1 wherein R^3 is selected from group A, pyridinyl, pyrimidinyl, imidazoyl, oxadiazoyl, triazolyl and pyrazinyl any of which are unsubstituted or substituted with 1, 2 or 3 substitutents selected from C_{1-6} alkyl, C_{1-6} alkoxy, halosubstitutedC_{1-6} alkoxy, hydroxy, cyano, halo, sulfonyl, $CONH_2$ and $COOH$.

6. (Canceled).

7. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 1.

8. (Original) A pharmaceutical composition as claimed in claim 7 further comprising a pharmaceutical carrier or diluent thereof.

9. (Previously presented) A method of treating a mammal suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said mammal a therapeutically effective amount of a compound as claimed in claim 1.

10. (Previously presented) The method as claimed in claim 9, wherein said condition is selected from an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis and osteoporosis

11. (Previously presented) The method as claimed in claim 10, wherein said pain is selected from inflammatory pain, viseral pain, cancer pain, neuropathic pain, lower back pain, muscular sceletal, post operative pain, acute pain and migraine.

12. (Previously presented) The method as claimed in claim 9, wherein said mammal is a human.